Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Prostate Cancer Treatment Considerations in Patients of Low Socioeconomic Status

Men of low socioeconomic status (SES) are more likely to present with metastases when they are diagnosed with prostate cancer... Read More

Prostate Cancer Mortality, Treatment in the US Differ By Region

Prostate cancer (PCa) epidemiology and management in the United States have been found to differ across regions. It is well... Read More

Psychosocial Concerns Common After Prostate Cancer Treatment

Psychosocial problems that adversely affect quality of life are common among men after receiving treatment for prostate cancer (PCa), and... Read More

Prostate Cancer Salvage Combo Benefits Confirmed

Final results of a phase 3 trial confirm the progression-free survival (PFS) benefit of adding short-term androgen suppression to radiotherapy... Read More

Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors

Neoadjuvant therapy that combines abiraterone acetate plus prednisone (AAP) and leuprolide prior to radical prostatectomy significantly reduces tumor size in... Read More

Dementia Not Linked to ADT for Prostate Cancer

New research may ease concerns that androgen deprivation therapy (ADT) contributes to dementia in patients with prostate cancer (PCa). Read... Read More

Study: Private Payer Coverage of Prostate MRI Lagging

Prostate magnetic resonance imaging (MRI) has becoming increasingly important in diagnosing and managing prostate cancer (PCa), but private payer coverage of prostate... Read More

The Potential Role for PARP Inhibitors in Prostate Cancer

Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for... Read More

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

PSA doubling time (PSADT) can predict oncologic and survival outcomes among men who receive brachytherapy for localized prostate cancer (PCa),... Read More

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Selected patients at elevated risk for biochemical recurrence of prostate cancer (PCa) following radical prostatectomy (RP) may benefit from tailored... Read More

1 2 3 10